Active Funded Projects

Updated Oct. 7, 2020
Data provided by University at Buffalo Sponsored Projects Services
Additional information on each funded project is also included where possible

Award Principal Investigator Award Name Award Type Sponsor Name Award Start Date Award End Date Total Cost
Balthasar, Dr. Joseph Catch and Release Immunotoxins: CAR-Bombs for Cancer Federal National Cancer Institute 07-Dec-2016 30-Nov-2021 1,816,235.00
Balthasar, Dr. Joseph Center for Protein Therapeutics Nonfederal Multiple Sponsors 01-Sep-2017 31-Aug-2021 5,324,501.70
Balthasar, Dr. Joseph Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors Federal National Cancer Institute 01-Jun-2020 31-May-2025 1,814,481.00
Balthasar, Dr. Joseph Evaluation of transient inhibition of cetuximab-tumor binding as a strategy to overcome the "binding-site barrier" Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Balthasar, Dr. Joseph Investigation of Effects of Novel Nanobodies on SARS-CoV-2 Binding, ACE2 Internalization Kinetics, and SARS-CoV-2 Infection Efficiency Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Balthasar, Dr. Joseph Targeted Delivery of Matrix Modulating Enzymes to Improve Antibody Distribution within Solid Tumors Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Balu-Iyer, Dr. Sathy V HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics Federal National Heart Lung and Blood Institute 05-Oct-2015 31-Dec-2020 1,593,611.46
Balu-Iyer, Dr. Sathy V Prediction of immunogenicity and its impact on PK of subcutaneously / intramuscularly administered protein therapeutics Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Bies, Dr. Robert R. Physiologically-based model of the female reproductive tract: vaginal and intrauterine delivery components- Support New Approaches to Improve Product Manufacturing and Quality Federal US Food and Drug Administration 26-Sep-2018 25-Sep-2022 888,097.00
Bies, Dr. Robert R. Pharmacokinetics of sedatives - Understanding a modifiable risk factor for pediatric delirium Federal Flow Through Childrens Research Institute 01-Sep-2019 31-Jul-2024 29,075.00
Bies, Dr. Robert R. Film Antiretroviral Microbicide Evaluation Federal Flow Through Magee-Womens Research Institute and Foundation 01-Jun-2019 31-May-2021 195,814.00
Blanco, Dr. Javier Defining the Contribution of Cellular Hypoxia to the Cardiotoxicity of Anticancer Anthracyclines and Trastuzumab Federal National Institute of General Medical Sciences 01-Sep-2019 31-Aug-2021 248,247.46
Blanco, Dr. Javier Understanding the Molecular Underpinnings of Anthracycline-related Cardiomyopathy in Childhood Cancer Survivors Nonfederal Board of Trustees of the University of Alabama Birmingham 01-Feb-2019 31-Jan-2022 64,369.00
Blanco, Dr. Javier Evaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and Leukemia Federal National Cancer Institute 23-Sep-2019 31-Aug-2021 438,625.00
Blanco, Dr. Javier The Who and Why of Anthracycline-related Cardiotoxicity in Childhood Cancer Survivors Nonfederal Board of Trustees of the University of Alabama Birmingham 01-Jul-2019 30-Jun-2022 37,238.00
Chilbert, Dr. Maya Rachael Comparison of Triple Theraply with Apixaban vs. Rivaroxaban Nonfederal American College of Clinical Pharmacy 01-Jul-2020 30-Jun-2021 4,000.00
Jacobs, Dr. David Matthew Impact of an Integrated Pharmacist and Primary Care Collaborative Transitions of Care Program on Clinical and economic Outcomes among High Risk Patients Nonfederal ASHP Research and Education Foundation 01-Jul-2019 30-Jun-2021 75,000.00
Jacobs, Dr. David Matthew Impact and feasibility of establishing a Community Health Worker Program within Community Pharmacy Settings Nonfederal Community Pharmacy Foundation 01-Jan-2020 31-Dec-2020 39,533.00
Jacobs, Dr. David Matthew A Clinical Integrated Community Pharmacy Network-Academic Partnership to Improve Diabetes Care in New York State Federal Flow Through Community Pharmacy Enhanced Services Network 01-Jan-2020 31-Dec-2020 15,000.00
Jacobs, Dr. David Matthew A qualitative study to understand patient and social factors related to nebulizer use at the transition of care in COPD Nonfederal Mylan Incorporated 15-Nov-2019 01-Oct-2021 22,104.00
Jusko, Dr. William J Mechanistic Pharmacokinetics and Pharmacodynamics Federal National Institute of General Medical Sciences 01-May-2019 30-Apr-2024 2,891,677.00
Krzyzanski, Dr. Wojciech Population PK Model of Indomethaicin in Preterm Infants Nonfederal Childrens Mercy Hospital 14-Nov-2019 13-Nov-2021 10,000.00
Ma, Dr. Qing Doravirine Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals Nonfederal Merck Sharp and Dohme Corporation 04-Jun-2019 04-Jun-2021 142,500.01
Ma, Dr. Qing Bictegravir in the Elderly Living with HIV: Impact of Polypharmacy and Multimorbidity Nonfederal Gilead Sciences Incorporated 01-Oct-2019 29-Sep-2022 5,000.00
Ma, Dr. Qing Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV Federal National Institute on Aging 01-May-2020 28-Feb-2025 4,006,139.00
Mager, Dr. Donald E Immunologic and Neurodevelopmental Consequences of Neonatal Anemia and Thrombocytopenia and their Treatments Federal Flow Through Childrens Hospital of Boston 01-Sep-2018 30-Jun-2023 644,233.00
Mager, Dr. Donald E Tumor Kinetic and Survival/Dropout Modeling of Durvalumab for Multiple Cancer Types Nonfederal MedImmune 16-May-2019 15-May-2021 39,764.00
Mager, Dr. Donald E Optimizing GVHD Prevention with Systems Pharmacology Models Federal Flow Through Beckman Research Institute of the City of Hope 01-Jun-2019 31-May-2024 551,996.00
Mager, Dr. Donald E Mechanistic PKPD modelling of biologic treatments in lymphoid leukemia for better understanding of efficacy and safety Foreign Institut de Recherches Internationales Servier 01-Aug-2019 31-Jul-2022 227,060.00
Meaney, Dr. Calvin J T Regulatory Cell Response to Erythropoiesis Stimulating Agents Post-Renal Transplantation Nonfederal American College of Clinical Pharmacy 01-Nov-2018 31-Oct-2020 5,000.00
Morris, Dr. Marilyn E SBIR: Development of Novel PDE4B Inhibitors to Treat Alcohol Use Disorder Federal Flow Through Codex BioSolutions Incorporated 23-Sep-2019 22-Sep-2021 73,459.00
Morse, Dr. Gene University of Rochester HIV/AIDS Clinical Trials Unit Federal Flow Through University of Rochester 01-Dec-2013 30-Nov-2020 423,493.00
Morse, Dr. Gene Clinical Pharmacology Quality Assurance Federal National Institute of Allergy & Infectious Disease 30-May-2015 29-May-2021 10,687,100.92
Morse, Dr. Gene HIV Research Training Program Federal Fogarty International Center 01-Apr-2016 28-Feb-2021 1,884,534.00
Morse, Dr. Gene Global Infectious Diseases Research Training Program Federal Fogarty International Center 11-Apr-2018 28-Feb-2023 1,125,653.00
Morse, Dr. Gene Laboratory Center (LC), AIDS Clinical Trails Group (ACTG) [UM1AI106701] Federal Flow Through University of California at Los Angeles 01-Dec-2018 30-Nov-2020 683,700.00
Morse, Dr. Gene ACTG Precautionary and Prohibited Medications Database Federal Flow Through University of California at Los Angeles 01-Dec-2018 30-Nov-2020 380,000.00
Qu, Dr. Jun Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity URF (AWD00001405) Federal Flow Through University of Rochester 01-Feb-2017 31-Jan-2022 467,931.00
Qu, Dr. Jun GMPS-GMPR axis melanoma progression and therapy Federal Flow Through Wake Forest University Health Sciences 23-Nov-2018 30-Apr-2023 102,352.00
Qu, Dr. Jun Comprehensive characterization of upregulated proteases in diseased vs normal tissues Nonfederal AbbVie Incorporated 19-Jun-2019 31-Dec-2020 190,000.00
Qu, Dr. Jun Novel LC-MS strategies for comprehensive investigations of Circulating Immune Complext and MHC Presenting Peptides Nonfederal GlaxoSmithKline 08-Jul-2019 01-Jun-2021 289,493.00
Qu, Dr. Jun Neuroinflammation-related phosphoprotein signaling pathways as potential therapeutic targets for GWI using an established animal model Federal Flow Through West Virginia Univ. Research Corp. on behalf of West Virginia Univ. 01-Feb-2020 31-Jan-2021 103,669.00
Qu, Dr. Jun The Network Biology of Pathogen-Host Interactions Driving Exacerbation in Chronic Obstructive Pulmonary Disease (COPD) Federal Flow Through Buffalo Institute for Medical Research 15-Sep-2019 14-Sep-2022 335,351.00
Qu, Dr. Jun Highly sensitive multiplexed targeted mass spectrometric assays of proteins/peptides of significance in obesity research Federal Flow Through Pacific Northwest National Laboratory 19-Feb-2020 31-Jul-2023 618,520.00
Qu, Dr. Jun UB CAT: Epigenetic Drug Discovery Platform For Methylation Inhibitors Nonfederal CH3 BioSystems LLC 01-Jul-2020 30-Jun-2021 2,500.00
Qu, Dr. Jun High-resolution, robust quantitative investigation of intra-tissue distribution of biotherapeutics and key biomarkers by LC-MS, using novel spatially-resolved micro-sampling devices fabricated by advanced UV-laser-curing photopolym Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Ramanathan, Dr. Murali The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression Federal US Army Medical Research Acquisition Activity 01-Jul-2020 30-Jun-2023 957,000.00
Shah, Dr. Dhavalkumar Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics Federal National Institute of General Medical Sciences 01-May-2015 31-Mar-2021 1,650,448.00
Shah, Dr. Dhavalkumar Development of a quantitative systems pharmacology (QSP) Model to Support Clinical Translation of adeno-associated virus (AAV) Vectorized Brain Delivery of Anti-a-Synuclein (AS) Antibody Foreign AstraZeneca UK Limited 13-Jul-2020 12-Jul-2021 80,000.00
Shah, Dr. Dhavalkumar Quantitative Evaluation of AAV9 Mediated Brain Delivery of Protein Therapeutics Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Shah, Dr. Dhavalkumar Translational PBPK Model for Pulmonary Disposition of Protein Therapeutics Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Shah, Dr. Dhavalkumar Expansion of Platform PBPK Model to Characterize TMDD of Antibody in the Brain Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Shah, Dr. Dhavalkumar Pharmacokinetics-Pharmacodynamics (PK-PD) of Enhanced Effector Function (EEF) ADC Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Shah, Dr. Dhavalkumar Targeting Transferrin Receptor (TfR) to Improve Ocular Exposure of Protein Therapeutics Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Straubinger, Dr. Robert M Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer Federal National Cancer Institute 01-Jul-2015 31-Aug-2021 2,156,820.00
Straubinger, Dr. Robert M Large-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy development Federal National Cancer Institute 21-Dec-2018 30-Nov-2020 398,683.00
Straubinger, Dr. Robert M Strategies for enhancing mAb delivery and distribution within tumors Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Tornatore, Dr. Kathleen M Age and Race Influences on Immunosuppression after Renal Transplant Federal National Institute on Aging 15-Aug-2018 30-Jun-2023 3,507,814.00
Tsuji, Dr. Brian T Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs Federal National Institute of Allergy & Infectious Disease 20-Dec-2019 30-Nov-2024 3,920,362.00
Woo, Dr. Sukyung Overcoming Resistance to Anti-VEGF Therapy with Predictive Modeling Nonfederal American Cancer Society 09-Dec-2019 30-Jun-2021 298,793.66
Woo, Dr. Sukyung Evaluating Determinants of PK, Tissue Distribution, and Efficacy of siRNA-antibody Conjugates Nonfederal University at Buffalo Center for Protein Therapeutics 1-Sep-20 30-Jun-21 100,000.00
Xu, Dr. Ying SBIR - Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease Federal Flow Through Tetra Discovery Partners 20-Sep-2016 31-Aug-2021 642,120.48
You, Dr. Young Jae NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers Federal National Institute of General Medical Sciences 01-Mar-2015 31-Jan-2021 147,604.00
You, Dr. Young Jae Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers Federal Flow Through Board of Regents of the University of Oklahoma Health Sciences Center 09-Dec-2019 31-Jul-2021 146,711.00